Thornhill Research & Rostrum Medical Announce Technology Development Agreement

TORONTO, ON  Thornhill and Rostrum celebrate the finalization of a Technology Development Agreement which includes the licensing of certain Thornhill IP and an investment by Rostrum into Thornhill. This agreement is aimed to further Rostrum’s development of its Pulmonary Health Monitoring during ventilation, in ICU, OR and ER applications while supporting Thornhill’s commercialization efforts of their own innovative products.

This Technology Development Agreement is a great example of the important role intellectual property plays in ensuring a healthy and vibrant medical technology ecosystem in Canada
— Kipton Lade, President

For the full press release click here

Previous
Previous

Qvella Raises US$20M in Series B Financing to Fund Clinical Trials, On-Going Research, Team Expansion, and Manufacturing Buildup

Next
Next

Pre-CAAP Company: Iris Technologies Releases Powerful Testimonial Video